Literature DB >> 26512768

An overview of normocalcemic primary hyperparathyroidism.

Monika Pawlowska1, Natalie E Cusano.   

Abstract

PURPOSE OF REVIEW: Normocalcemic primary hyperparathyroidism (PHPT) received special attention in the publication of the conference proceedings from the Fourth International Workshop on the Management of Asymptomatic PHPT, although much remains unknown about the disorder. RECENT
FINDINGS: Observational studies have found that despite maintaining normocalcemia, patients with normocalcemic PHPT have a high incidence of kidney stones and osteoporosis. Small studies focusing on the cardiovascular implications of normocalcemic PHPT have shown a possible association with hypertension and an atherogenic lipid profile, but not insulin resistance. Recent data from small cohorts show that subjects with normocalcemic PHPT respond to medical therapy and have a positive densitometric response following parathyroid surgery.
SUMMARY: The available evidence suggests that patients with normocalcemic PHPT develop complications of PHPT, despite having normal calcium levels. Most data come from referral populations and information regarding a mild, asymptomatic form of the disease is lacking. Future research requires a standardized approach to the diagnostic criteria of normocalcemic PHPT.

Entities:  

Mesh:

Year:  2015        PMID: 26512768     DOI: 10.1097/MED.0000000000000198

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  13 in total

1.  US-guided microwave ablation for primary hyperparathyroidism: a safety and efficacy study.

Authors:  Bo-Qiang Fan; Xiao-Wei He; Huan-Huan Chen; Wei-Ming Zhang; Wei Tang
Journal:  Eur Radiol       Date:  2019-03-19       Impact factor: 5.315

Review 2.  Primary Hyperparathyroidism.

Authors:  John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2018-11-01       Impact factor: 5.958

Review 3.  Current opinions on nephrolithiasis associated with primary hyperparathyroidism.

Authors:  Xiaoming Cong; Luming Shen; Xiaojian Gu
Journal:  Urolithiasis       Date:  2018-01-19       Impact factor: 3.436

4.  Is parathyroidectomy safe and effective in patients with normocalcemic primary hyperparathyroidism?

Authors:  Emanuela Traini; Rocco Bellantone; Serena Elisa Tempera; Salvatore Russo; Carmela De Crea; Celestino Pio Lombardi; Marco Raffaelli
Journal:  Langenbecks Arch Surg       Date:  2018-03-14       Impact factor: 3.445

5.  High blood pressure as the first manifestation and multiple organ dysfunction in primary hyperparathyroidism: a case report.

Authors:  Yongle Jing; Chengzhi Lu; Dasheng Xia; Wei Xia; Yuli Wu
Journal:  Hypertens Res       Date:  2020-04-16       Impact factor: 3.872

6.  A retrospective study of elevated post-operative parathormone in primary hyperparathyroid patients.

Authors:  Shaobo Cao; Ya Hu; Yiming Zhao; Zhe Su; Zhiyan Xu; Xiang Gao; Quan Liao; Yupei Zhao
Journal:  Oncotarget       Date:  2017-08-24

7.  Normocalcemic Hyperparathyroidism: Study of its Prevalence and Natural History.

Authors:  Marian Schini; Richard M Jacques; Eleanor Oakes; Nicola F A Peel; Jennifer S Walsh; Richard Eastell
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

8.  Changes in bone mineral density after parathyroidectomy in patients with moderate to severe primary hyperparathyroidism.

Authors:  Shuai Lu; Maoqi Gong; Yejun Zha; Aimin Cui; Chen Chen; Hao Yang; Weitong Sun; Kehan Hua; Wei Tian; Xieyuan Jiang
Journal:  J Int Med Res       Date:  2020-10       Impact factor: 1.671

9.  Serum Calcium to Phosphorous (Ca/P) Ratio Is a Simple, Inexpensive, and Accurate Tool in the Diagnosis of Primary Hyperparathyroidism.

Authors:  Bruno Madeo; Elda Kara; Katia Cioni; Silvia Vezzani; Tommaso Trenti; Daniele Santi; Manuela Simoni; Vincenzo Rochira
Journal:  JBMR Plus       Date:  2017-11-02

10.  Normocalcaemic hyperparathyroidism and primary hyperparathyroidism: least significant change for adjusted serum calcium.

Authors:  Marian Schini; Richard Jacques; Eleanor Oakes; Nicola Peel; Jennifer S Walsh; Richard Eastell
Journal:  Eur J Endocrinol       Date:  2021-01       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.